The costs of asthma disease on the healthcare system

Asthma is a lung disease characterized by coughing, episodic wheezing and shortness of breath resulting from airway inflammation and hypersensitivity. It is thought that both the incidence and prevalence of asthma increase depending on the increase in lifestyle and environmental risk factors. In this study, we aimed to analyze the cost of patients with asthma in our country and to consider the reasons that increase the cost of asthma. The data of 100 patients (fifty female and fifty male) followed up with a diagnosis of asthma were analyzed in this study. The mean total cost of antibiotics was 1278.157±3645.403. The mean hospital costs of the patients were 2623.022±7519.284 and the mean intensive care unit (ICU) cost of the asthmatic patients in the ICU was 9557.877±114371.217. Statistically significant relations were detected between length of stay in hospital and total hospital cost (THC) (P=0.000), length of stay in the ICU and THC (p=0.000), length of stay in the service and THC (p=0.011), antibiotic use and THC (p= 0.018) and total cost of ICU stay and THC. Asthma affects people at various levels and causes significant costs on governments. Effective management of the disease can be achieved by eliminating and preventing both internal and external factors causing the disease and improving asthma education.

PDF

___

1. Villarroel MA, Blackwell DL. Percentage of adults aged 18–64 years with current asthma, by State-National Health Interview Survey,(Dagger) 2014– 2016. Atlanta (GA): Centers Disease Control 1600 Clifton Rd; 2018.30333 USA.

2. Mazurek JM. Prevalence of asthma, asthma attacks, and Emergency Department visits for asthma among working adults—national health interview survey, 2011—2016. MMWR Morb Mortal Wkly Rep. 2018;67.

3. Akinbani LJ, Moorman JE, Bailey C. Centers for disease control and prevention. trends in asthma prevalence, health care use, and mortality in the United States, 2001–2010. Hyattsville MD: National Center for Health Statistics Data Brief. 2012;94:1–7.

4. Nunes C, Pereira AM, Morais-Almeida M. Asthma costs and social impact. Asthma Res Pract. 2017;3:1.

5. Nurmagambetov T, Kuwahara R, Garbe P. The Economic Burden of Asthma in the United States, 2008–2013. Ann Am Thorac Soc. 2018;15:348–56.

6. Urmi Bhaumik, Susan J Sommer, Ryan Lockridge, et al. Woods (2019): community asthma initiative: cost analyses using claims data from a medicaid managed care organization. J Asthma. 2020;57:286-94.

7. O’Toole J, Mikulic L, Kaminsky DA. Epidemiology and pulmonary physiology of severe asthma. Immunol Allergy Clin. 2016;36:425–38. 8. To T, Stanojevic S, Moores G, et al. Global asthma prevalence in adults: findings from the crosssectional world health survey. BMC Public Health. 2012;19:204.

9. Yanagisawa S, Ichinose M. Definition and diagnosis of asthmae COPD overlap (ACO). Allergol Int. 2018;67:172-8.

10. McQueen RB, Sheehan DN, Whittington MD, et al. Cost-effectiveness of biological asthma treatments: a systematic review and recommendations for future economic evaluations. PharmacoEconomics. 2018;36:957-71.

11. Global Initiative for Asthma. Global strategy for asthma management and prevention, 2017. http://www.ginasthma.org.Accessed Dec 2017.

12. Cox LS, Murphey A, Hankin C. The cost-effectiveness of allergen immunotherapy compared with pharmacotherapy for treatment of allergic rhinitis and asthma. Immunol Allergy Clin N Am. 2020;40:69–85.

13. Mihaela S Stefan, Meng-Shiou Shieh, Kerry A Spitzer, et al. Lindenauer. association of antibiotic treatment with outcomes in patients hospitalized for an asthma exacerbation treated with systemic corticosteroids. JAMA Intern Med. 2019;179:333–9.

14. Lous P, Wise SK. Epidemiology and economic burden of asthma. Int Forum Allergy Rhinol. 2015;5:7–10. 15.

15. Costa E, Caetano R, Werneck GL, et al. Estimated cost of asthma in outpatient treatment: a real-world study. Rev Saude Publica. 2018;52:27.